---
document_datetime: 2025-05-08 12:06:22
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tacforius-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tacforius-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6262882
conversion_datetime: 2025-12-28 01:42:52.58507
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tacforius

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 08/05/2025                          |                                             | SmPC and PL                      | To update SmPC section 4.4 to amend a warning on |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000266646                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update SmPC section 4.4 to amend a warning on Lymphoproliferative disorders and malignancies, and section 4.8 to amend a warning on Neoplasms benign, malignant and unspecified (incl. cysts and polyps), and to update section 4 of the PL accordingly, following assessment of the same change for the reference product Advagraf. Additionally, the MAH has taken the opportunity to introduce minor editorial changes to sections 4.2 and 5.1 of the SmPC, as well as section 4 of the PL, in line with the EN PI text of the reference product. Furthermore, the MAH has taken the opportunity to perform editorial corrections to the PI in BG, EL, and SV to align with the reference product and the EN PI text of Tacforius, to correct typographic errors, and to remove the local representative for the UK (Northern Ireland) in accordance with the   |            | Lymphoproliferative disorders and malignancies, and section 4.8 to amend a warning on Neoplasms benign, malignant and unspecified (incl. cysts and polyps), and to update section 4 of the PL accordingly, following assessment of the same change for the reference product Advagraf.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000257502 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/03/2025 |                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |                       |                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|-------------------|
| Variation type IB / | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a. - To update section 4.6 of the SmPC has been updated to reflect the results of the study that tacrolimus crosses the placenta and the risk of hyperkalaemia in newborns. The package leaflet is updated accordingly. In addition the MAH has taken this opportunity to make minor corrections in line with the current QRD version and to amend the details of the local representative for EL and CY.. | 03/12/2024 | SmPC, Annex II and PL | EMA/VR/0000236795 |